Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.
Price history
Loading CMMB daily closes…
Loading price history…
Pipeline assets
CM-101
Phase 2 · ActiveModality: monoclonal antibody
Target CCL24
Indications
Primary sclerosing cholangitis (PSC)(Phase 2)
Systemic sclerosis (SSc)(Phase 2)
NASH / liver fibrosis(Phase 2)
Catalysts
— second half of 2024
Status note Humanized monoclonal antibody targeting CCL24. Phase 2 study in PSC ongoing; Phase 2 ABATE trial in SSc enrolling (IND cleared Feb 21, 2023); Phase 2a liver fibrosis biomarker trial in NASH completed.
Per-asset detail extracted from the 10-Q filed 2023-05-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
ADAR1 Capital Management
80,000
no change
0.01%
2026-08-14
Ikarian Capital
51,793
no change
0.01%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.